Form 4: Keith Woods Reports Stock Option Grant in TScan Therapeutics
SEC Form 4 Filing
Director Keith Woods received a stock option grant for 47,500 shares of TScan Therapeutics, Inc. on June 12, 2024.
Summary
- Keith Woods, a director of TScan Therapeutics, Inc., reported a transaction involving derivative securities.
- On June 12, 2024, Woods was granted a stock option to purchase 47,500 shares of TScan Therapeutics' voting common stock at an exercise price of $8.88.
- The options vest and become exercisable on the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service.
- Following the transaction, Woods directly owns 47,500 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock options, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation awarded to directors.
Stakeholder Impact
- The grant of stock options aligns the director's interests with those of the shareholders, incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of stock option grant |
| 06/12/2025 | First possible vesting date for the stock options |
| 06/11/2034 | Expiration date of the stock options |
| 06/14/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.